Prevention of type 1 diabetes: Today and tomorrow

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 8, 2010, Pages 602-605

  Cernea, Simona ^a,b   Dobreanu, Minodora ^b,c   Raz, Itamar ^d  

^a Diabetes Nutrition and Metabolic Diseases Outpatient Unit   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Clinical Emergency County Hospital   (Romania)

^d HEBREW UNIVERSITY   (Israel)

Author keywords

Prevention approaches; Therapy; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; C PEPTIDE; CD20 ANTIBODY; CD3 ANTIBODY; CYCLOSPORIN; DACLIZUMAB; DIAPEP 277; DOCOSAHEXAENOIC ACID; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ALUMINUM; GLUTEN; HUMAN INSULIN; INSULIN; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMEGA 3 FATTY ACID; OTELIXIZUMAB; RITUXIMAB; SYNTHETIC PEPTIDE; TEPLIZUMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VITAMIN D;

ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC PATIENT; DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LONG TERM CARE; METABOLIC REGULATION; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REHABILITATION; REVIEW; SECONDARY PREVENTION; T LYMPHOCYTE ACTIVATION; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, INTRANASAL; ADULT; ANTIGENS, CD20; ANTIGENS, CD3; CHILD; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN;

EID: 78049472461     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1138     Document Type: Review

References (25)

1. International Diabetes Federation. Diabetes Atlas (2nd edn). Executive summary. 2003; 1-58.
2. Cerná M. Genetics of autoimmune diabetes mellitus. Wien Med Wochenschr 2008; 158: 2-12.
3. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual ß-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
4. Stiller CR, Dupré J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362-1367.
5. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin dependent diabetes mellitus. N Engl J Med 1988; 319: 599-604.
6. Eisenbarth GS, Srikanta S, Jackson R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985; 2: 271-276.
7. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996; 9: 379-383.
8. Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care 2009; 32: 1769-1782.
9. Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 2008; 4: 334-343.
10. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010; 33: 826-832.
11. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT31 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1753-1769.
12. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3- antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
13. Herold KC, Gitelman S, Greenbaum C, et al. Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132: 166-173.
14. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53: 614-623.
15. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-2152.
16. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Comp 2005; 19: 238-246.
17. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-1920.
18. Raz I, Elias D, Avron A, et al. γ-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, doubleblind, phase II trial. Lancet 2001; 358: 1749-1753.
19. Schloot N, Meierhoff G, Lengyel C, et al. Effect of heat shock protein peptide DiaPep277 on ß-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomised, double blind phase II trials. Diabetes Metab Res Rev 2007; 23: 276-285.
20. Raz I, Avron A, Tamir M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007; 23: 292-298.
21. Chatenoud L, Bluestone J. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7: 622-632.
22. Cernea S, Pozzilli P. New potential treatments for protection of pancreatic B-cell function in type 1 diabetes. Diabet Med 2008; 25: 1259-1267.
23. Ablamunits V, Sherry NA, Kushner JA, Herold KC. Autoimmunity and γ cell regeneration in mouse and human type 1 diabetes the peace is not enough. Ann N Y Acad Sci 2007; 1103: 19-32.
24. Bonner-Weir S. Perspective: postnatal pancreatic γ cell growth. Endocrinology 2000; 141: 1926-1929.
25. Sherry N, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 mAb by enhancing recovery of beta cells. Endocrinology 2007; 148: 5136-5144.